The natural course of myasthenia gravis (MG) is not well known. In the early series the diagnosis was probably limited to the more severely affected patients with mortality rates of 30-40%.' 2 Since the introduction of anticholinesterases in 1934 the diagnosis was facilitated in less prominent cases although a reaction may be absent in the ocular cases. Thymectomy is generally thought to have improved the natural course in early onset cases without thymoma, but some doubt has been expressed because of the lack of randomised prospective studies. Improved intensive care facilities and the use of prednisone, immunosuppressive drugs and plasma-exchange are of benefit especially to the 20% severely affected patients with intermittent respiratory insufficiency. The use of new diagnostic tools such as single-fibre electromyography, EMG with ischaemia, and the determination of antibodies to acetylcholine receptor proteine (AChR) allow a more accurate diagnosis in mild cases and exclude other myasthenic syndromes and pseudomyasthenia. As a result these procedures include mild cases which probably remained undiagnosed in earlier series, thereby improving the prognosis.
Between 1961-65 I studied 58 patients with MG living in Amsterdam. They probably comprised all the patients diagnosed with MG at that time. This epidemiologically defined cohort was followed until 1985. Since these patients were in part survivors of a larger population of MG patients, all the patients diagnosed in the University Department ofNeurology from 1926 and living in Amsterdam, were reviewed retrospectively. Thymectomy in non thymoma patients was not used before 1965 while prednisone and azathioprine were only used after 1970 in some patients and affected the final outcome in only three. Therefore the evolution of their signs might be the natural course of MG if treatment with anticholinesterases is assumed not to influence the outcome. A first report was given in a previous paper. The natural course ofmyasthenia gravis: a long termfollow up study had a period of exacerbation in a previously stable course; this could be ascribed to hyperthroidism in one and to emotional stress in two (these exacerbations are not listed in table 4). Thymomas were detected in nine men and five women; five were present in the early onset group, and nine in the late onset group. In all patients with thymomas MG was generalised; maximum severity was mild in one patient, moderate in four and severe in nine. Further data are summarised in table 5.
Myasthenic crisis and death Eighteen patients died in a myasthenic crisis, 13 within three years after onset (three in the period before prostigmin), three in the sixth year after onset, and two patients (eight and 17 years respectively after onset) in a crisis precipitated by an operation and an airway infection. Eight of 14 thymoma patients died, four of these shortly after thymomectomy (table 5) . Prednisone was not prescribed or intratracheal artificial ventilation given in any of these patients.
One death concerned a boy aged one year who developed a severe bulbar weakness during a varicella infection. The diagnosis was made when his monozygotic twin brother developed the same infection 10 days later. This boy had moderate oculobulbar signs in infancy with a good reaction to prostigmin, and mild intermittent ocular signs thereafter. There were five survivors of a myasthenic crisis (n = 23, table 6). One was a girl aged 17 months, who developed severe oculobulbar weakness and apnoea during an infection. She had mild myasthenic signs in childhood and went into a complete remission at the age of 20. Although no anti-AChR antibodies were found in these two patients as adults, the clinical course and the favourable reartion to anticholinesterases suggests an acquired rather than a congenital myasthenia.
The three adult survivors of the myasthenic crisis were the thymoma patients numbers 13 and 14 (table 5) and a woman aged 60 who improved to stage 2 when treated with prednisone. In this patient a thymoma was excluded at autopsy after cardiac death aged 75. tOne patient treated with thymomectomy. 14) .
Muscle atrophy
Muscle atrophy was clinically evident in seven patients. In six women with longstanding disease atrophy was localised in the shoulders and upper arm muscles (n = 4) or in the face and tongue (n = 2). In one young man a generalised muscle atrophy developed within a few months after thymomectomy when he was artificially ventilated. Autopsy showed neurogenic changes in the muscles and normal peripheral nerves. 7 In 9 of the 20 patients with generalised MG the quadriceps were found to be abnormal at biopsy: lymphorrhages were found in two patients with a thymoma, neurogenic atrophy and lymphorrhages in 5 patients (four with a thymoma) and neurogenic changes only in 2 patients without a thymoma.
Neonatal myasthenia Two cases of neonatal myasthenia occurred in the offspring of two patients who had previously had one and two normal children respectively during their disease. In total 11 children were born to seven patients during their disease. The incidence of neonatal myasthenia was 18% of the pregnancies during MG. (These cases were not included in the series.) This incidence is not different from the 12% reported.8
Antibodies
Antibodies to striated muscle were found in 18 of 51 patients. In all 11 patients with thymomas the titres were much higher than the seven late onset patients without thymomas. Antinuclear factors were found in 18 of the 46 patients; the incidence was higher (p < 0 05) in patients with thymomas (seven out of 11), than in patients without thymomas (11 out of 36).
In 1985 antibodies to AChR were found in 18 of 21 patients with generalised MG and in three of the six patients with ocular MG. The seronegative patients in the generalised group included the two patients with onset in infancy and one patient with a mild MG who went into remission.
Discussion
The incidence and prevalence of MG in this study is comparable with data from other recent studies (table  8) . The prevalence is higher than that reported by Kurtzke'3 who estimated a prevalence of40 per million as a result of various previous epidemiological investigations. His estimation of the annual incidence was four per million. The explanation of the higher prevalence is perhaps a more thorough case finding, which included patients no longer receiving specialist care. The higher prevalence in Norway" may also be explained in this way. An overall review ofthe patients with MG, living in Amsterdam and admitted to the neurological department in the periods between 1926-65 (table 1) suggests that the incidence of diagnosed cases with generalised MG and the death rate have not changed. Pure ocular MG was not diagnosed before 1955, possibly due to the difficulty in diagnosis. An alternative explanation is that these patients were not admitted for clinical observation, but this seems unlikely as all patients with uncommon diseases were admitted to hospital.
The predominance of women in the early onset The natural history that emerges from this study is as follows. After an uncertain onset, with spontaneous transitory remissions in about 20% of the patients, the disease gradually develops a maximum intensity in the first seven years, although about 15% may have their worst period later. About 25% of the patients will die, mainly in this first period. Spontaneous clinical remissions and substantial improvement may be expected from the second year after onset and may occur at any time thereafter, but the clinical course is unpredictable in the individual patient (table 5). The general trend in the survivors is that of a gradual improvement in the long term, a complete clinical remission (without medication) occurring in more than 20%; approximately 15%, usually with mild symptoms, do not change (table 5) . This general improvement was not merely the result of a subjective account by the patients and the improved ability to cope with their handicap. The clinical assessment in this study was based on quantified clinical tests,Id for most patients at multiple follow up examinations to assess their muscle strength and endurance.
If patients with thymomas and those who died early are excluded the early onset group had the same prognosis as the late onset group. An early death, without treatment with prostigmine, occurred in four of the early onset patients and in one patient with a thymoma (number 12). Patients with a thymoma usually had severe MG and a higher case fatality (8/14 table 5).
In table nine the results of this study are compared with those of two others from the same period.2"6
While the myasthenic death rates seem to be similar, the more favourable outcome in the present series is probably the result of the longer follow up. The impact of new therapies such as thymectomy in early onset patients and prednisone or immunosuppressive therapy in late onset patients, and in patients with thymomas, is reflected in the outcome of a series of 328 patients with generalised MG with onset between 1965-84 and a mean follow up of 12 years. '5 Complete clinical remission, with or without therapy, occurred in 37% and death in 9%. The latter was due to MG in 5 2% of the patients, who were not treated with prednisone, in 1-8% due to the side effects of prednisone or azathioprine and in 2% due to the invasiveness of their thymoma or thymoma associated myocarditis.
Associated diseases of probable autoimmune origin were present in three of 11 patients with thymomas and in 12 of 47 patients without thymomas. This frequency (25%) is probably higher than expected for the whole population although the prevalence of autoimmune diseases in a population studied over a long period is not known. Only rheumatoid arthritis in women had a definitely higher prevalence than expected from a population study'6 which yielded about the same prevalence as that in The Netherlands (expected age adjusted prevalence 3-25% means 15% in this study).
In three women a malignant disease was detected. This figure is not higher than may be expected'9 (age adjusted prevalence 2 4) and does not support the finding that the incidence of extrathymic neoplasms
